| pubmed-article:21137087 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:21137087 | lifeskim:mentions | umls-concept:C0032105 | lld:lifeskim |
| pubmed-article:21137087 | lifeskim:mentions | umls-concept:C0011881 | lld:lifeskim |
| pubmed-article:21137087 | lifeskim:mentions | umls-concept:C0005516 | lld:lifeskim |
| pubmed-article:21137087 | lifeskim:mentions | umls-concept:C0243095 | lld:lifeskim |
| pubmed-article:21137087 | lifeskim:mentions | umls-concept:C1328924 | lld:lifeskim |
| pubmed-article:21137087 | lifeskim:mentions | umls-concept:C1709694 | lld:lifeskim |
| pubmed-article:21137087 | lifeskim:mentions | umls-concept:C0936012 | lld:lifeskim |
| pubmed-article:21137087 | pubmed:issue | 8-9 | lld:pubmed |
| pubmed-article:21137087 | pubmed:dateCreated | 2010-12-7 | lld:pubmed |
| pubmed-article:21137087 | pubmed:abstractText | Diabetic nephropathy (DN) is the most common cause of end-stage renal disease and improved biomarkers would help identify high-risk individuals. The aim of this study was to discover candidate biomarkers for DN in the plasma peptidome in an in-house cross-sectional cohort (n=122) of type 1 diabetic patients diagnosed with normo-, micro-, and macroalbuminuria. | lld:pubmed |
| pubmed-article:21137087 | pubmed:language | eng | lld:pubmed |
| pubmed-article:21137087 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21137087 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:21137087 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21137087 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21137087 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21137087 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21137087 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21137087 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:21137087 | pubmed:month | Sep | lld:pubmed |
| pubmed-article:21137087 | pubmed:issn | 1862-8354 | lld:pubmed |
| pubmed-article:21137087 | pubmed:author | pubmed-author:HøjrupPeterP | lld:pubmed |
| pubmed-article:21137087 | pubmed:author | pubmed-author:TarnowLiseL | lld:pubmed |
| pubmed-article:21137087 | pubmed:author | pubmed-author:RossingPeterP | lld:pubmed |
| pubmed-article:21137087 | pubmed:author | pubmed-author:PociotFlemmin... | lld:pubmed |
| pubmed-article:21137087 | pubmed:author | pubmed-author:HubalekFranti... | lld:pubmed |
| pubmed-article:21137087 | pubmed:author | pubmed-author:PedersenLykke... | lld:pubmed |
| pubmed-article:21137087 | pubmed:author | pubmed-author:LajerMariaM | lld:pubmed |
| pubmed-article:21137087 | pubmed:author | pubmed-author:McGuireJames... | lld:pubmed |
| pubmed-article:21137087 | pubmed:author | pubmed-author:OvergaardJuli... | lld:pubmed |
| pubmed-article:21137087 | pubmed:author | pubmed-author:HansenHenning... | lld:pubmed |
| pubmed-article:21137087 | pubmed:copyrightInfo | Copyright © 2010 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim. | lld:pubmed |
| pubmed-article:21137087 | pubmed:issnType | Electronic | lld:pubmed |
| pubmed-article:21137087 | pubmed:volume | 4 | lld:pubmed |
| pubmed-article:21137087 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:21137087 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:21137087 | pubmed:pagination | 697-705 | lld:pubmed |
| pubmed-article:21137087 | pubmed:meshHeading | pubmed-meshheading:21137087... | lld:pubmed |
| pubmed-article:21137087 | pubmed:meshHeading | pubmed-meshheading:21137087... | lld:pubmed |
| pubmed-article:21137087 | pubmed:meshHeading | pubmed-meshheading:21137087... | lld:pubmed |
| pubmed-article:21137087 | pubmed:meshHeading | pubmed-meshheading:21137087... | lld:pubmed |
| pubmed-article:21137087 | pubmed:meshHeading | pubmed-meshheading:21137087... | lld:pubmed |
| pubmed-article:21137087 | pubmed:meshHeading | pubmed-meshheading:21137087... | lld:pubmed |
| pubmed-article:21137087 | pubmed:meshHeading | pubmed-meshheading:21137087... | lld:pubmed |
| pubmed-article:21137087 | pubmed:meshHeading | pubmed-meshheading:21137087... | lld:pubmed |
| pubmed-article:21137087 | pubmed:meshHeading | pubmed-meshheading:21137087... | lld:pubmed |
| pubmed-article:21137087 | pubmed:meshHeading | pubmed-meshheading:21137087... | lld:pubmed |
| pubmed-article:21137087 | pubmed:meshHeading | pubmed-meshheading:21137087... | lld:pubmed |
| pubmed-article:21137087 | pubmed:meshHeading | pubmed-meshheading:21137087... | lld:pubmed |
| pubmed-article:21137087 | pubmed:year | 2010 | lld:pubmed |
| pubmed-article:21137087 | pubmed:articleTitle | Finding diabetic nephropathy biomarkers in the plasma peptidome by high-throughput magnetic bead processing and MALDI-TOF-MS analysis. | lld:pubmed |
| pubmed-article:21137087 | pubmed:affiliation | Hagedorn Research Institute, Novo Nordisk A/S, Gentofte, Denmark. | lld:pubmed |
| pubmed-article:21137087 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:21137087 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
